Sign In
Last checked at 
28 Mar 2012 11:12
Hikma Pharmaceuticals PLC - Share Transactions
LONDON, 28 March 2012: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have exercised awards which vested on 19 March 2012 under the 2005 Long Term Incentive Plan ("LTIP"). The exercise price under the LTIP is £nil. The persons concerned elected to sell their shares as detailed below.
In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over the Company's Ordinary Shares of 10p each as detailed below.
PDMR | Type of Transaction | Exercised | Date | Price | Shares Sold | Outstanding Holding |
Bassam Kanaan
| Exercise of LTIP 2009 | 69,000 (0.04% ISC) | 28 March 2012 | £6.91 | 30,000 | 418,568 (0.21% ISC) |
Michael Raya | Exercise of LTIP 2009
| 46,000 (0.02% ISC) | 28 March 2012 | £6.91 | 46,000 | 12,200 (0.01% ISC) |
Jason Grenfell-Gardener
| Exercise of LTIP 2009 | 27,600 (0.01% ISC) | 28 March 2012 | £6.91 | 27,600 | Nil (0.00% ISC) |
- ENDS -
Enquiries:
Hikma Pharmaceuticals PLC
Henry Knowles +44 20 7399 2760
Company Secretary
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non‐branded generic and in‐licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.
Follow the stocks
